Triple Dose Of Good News At Heart Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Pioglitazone, prasugrel and telmisartan prove strong in studies’ data.
You may also be interested in...
Prasugrel Sales Force Poised For FDA Decision In June, Lilly Says
No indication that FDA will call an advisory committee review for prasugrel, according to the firm.
Prasugrel Sales Force Poised For FDA Decision In June, Lilly Says
No indication that FDA will call an advisory committee review for prasugrel, according to the firm.
Lilly’s Prasugrel Could Gain FDA Approval In June
Anti-clotting agent was granted a six-month priority review by FDA.